BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-588@pharmaconomics
DTSTAMP:20260707T041618Z
DTSTART;VALUE=DATE:20240308
DTEND;VALUE=DATE:20240309
SUMMARY:AVTX Phase 2 — abdakibart (estimated date)
DESCRIPTION:Phase 2 trial results for abdakibart in hidradenitis suppurativa are due ~ Mar 8\, 2024. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/ex-992avalocorporatepres.htm\n\nTrack it: https://pharmaconomics.com/e/588
URL:https://pharmaconomics.com/e/588
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AVTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR